Blockade of Myeloid Suppressor Cells Overcomes the Anti-PD-1/PD-L1 Resistance in KRAS-Driven and LKB1-Deficient NSCLC

被引：0
|
作者：
Li, R. [1 ]
Salehi-Rad, R. [1 ]
Momcilovic, M. [1 ]
Lim, R. [1 ]
Ong, S. [1 ]
Huang, Z. [1 ]
Tran, L. [1 ]
Zhe, J. [1 ]
Paul, M. [1 ]
Teitell, M. [1 ]
Minna, J. [2 ]
Krysan, K. [1 ]
Shackelford, D. [1 ]
Liu, B. [1 ]
Dubinett, S. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] UTSW, Dallas, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A11
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [21] Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Nowicki, Theodore S.
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    CANCER JOURNAL, 2018, 24 (01): : 47 - 53
  • [22] Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment
    Louis Boafo Kwantwi
    Clinical and Experimental Medicine, 2023, 23 : 3077 - 3091
  • [23] Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
    Abdel-Rahman, Omar
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 : 75 - 85
  • [24] Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy
    Zhulai, Galina
    Oleinik, Eugenia
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2022, 95 (03)
  • [25] STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC
    Skoulidis, F.
    Albacker, L.
    Hellmann, M.
    Awad, M.
    Gainor, J.
    Goldberg, M.
    Schrock, A.
    Gay, L.
    Elvin, J.
    Ross, J.
    Rizvi, H.
    Carter, B.
    Erasmus, J.
    Halpenny, D.
    Plodkowski, A.
    Long, N.
    Nishino-Habatu, M.
    Denning, W.
    Rodriguez-Canales, J.
    Villalobos, P.
    Cuentas, E. Parra
    Sholl, L.
    Sauter, J.
    Elamin, Y.
    Zhang, J.
    Leonardi, G.
    Wong, K.
    Stephens, P. J.
    Papadimitrakopoulou, V.
    Wistuba, I.
    Wolchok, J.
    Shaw, A.
    Janne, P.
    Rudin, C.
    Miller, V.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1815 - S1815
  • [26] PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
    Zhang, Yan
    Xiang, Cheng
    Wang, Yuling
    Duan, Yuanyuan
    Liu, Ci
    Zhang, Yajing
    ONCOTARGET, 2017, 8 (60) : 101535 - 101544
  • [27] Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
    Mabbitt, Joseph
    Roper, James A.
    Slack, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
    Bie, Fenglong
    Tian, He
    Sun, Nan
    Zang, Ruochuan
    Zhang, Moyan
    Song, Peng
    Liu, Lei
    Peng, Yue
    Bai, Guangyu
    Zhou, Bolun
    Gao, Shugeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
    Ken Masuda
    Hidehito Horinouchi
    Midori Tanaka
    Ryoko Higashiyama
    Yuki Shinno
    Jun Sato
    Yuji Matsumoto
    Yusuke Okuma
    Tatsuya Yoshida
    Yasushi Goto
    Noboru Yamamoto
    Yuichiro Ohe
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 245 - 251
  • [30] Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
    Musaelyan, Aram A. A.
    Lapin, Sergey L. V.
    Urtenova, Margarita A. A.
    Odintsova, Svetlana V. V.
    Chistyakov, Ivan V. V.
    Ulitin, Andrey M. M.
    Akopov, Andrey L. L.
    Orlov, Sergey V. V.
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (03)
12345